MX2024013326A - Composiciones y metodos para el tratamiento de enfermedades oculares - Google Patents

Composiciones y metodos para el tratamiento de enfermedades oculares

Info

Publication number
MX2024013326A
MX2024013326A MX2024013326A MX2024013326A MX2024013326A MX 2024013326 A MX2024013326 A MX 2024013326A MX 2024013326 A MX2024013326 A MX 2024013326A MX 2024013326 A MX2024013326 A MX 2024013326A MX 2024013326 A MX2024013326 A MX 2024013326A
Authority
MX
Mexico
Prior art keywords
compositions
methods
ocular diseases
treating ocular
disease
Prior art date
Application number
MX2024013326A
Other languages
English (en)
Spanish (es)
Inventor
Ted Yednock
Lori Taylor
Anita Grover
Donald Fong
Original Assignee
Annexon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Annexon Inc filed Critical Annexon Inc
Publication of MX2024013326A publication Critical patent/MX2024013326A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2024013326A 2022-04-29 2024-10-28 Composiciones y metodos para el tratamiento de enfermedades oculares MX2024013326A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263336539P 2022-04-29 2022-04-29
PCT/US2023/066393 WO2023212719A1 (en) 2022-04-29 2023-04-28 Compositions and methods for treating ocular diseases

Publications (1)

Publication Number Publication Date
MX2024013326A true MX2024013326A (es) 2024-12-06

Family

ID=88519880

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024013326A MX2024013326A (es) 2022-04-29 2024-10-28 Composiciones y metodos para el tratamiento de enfermedades oculares

Country Status (10)

Country Link
US (1) US20250313614A1 (enExample)
EP (1) EP4518896A4 (enExample)
JP (1) JP2025515485A (enExample)
KR (1) KR20250006238A (enExample)
CN (1) CN119136830A (enExample)
AU (1) AU2023262202A1 (enExample)
CA (1) CA3250843A1 (enExample)
IL (1) IL316218A (enExample)
MX (1) MX2024013326A (enExample)
WO (1) WO2023212719A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025184235A1 (en) * 2024-02-28 2025-09-04 Onl Therapeutics, Inc. Methods and compositions for treating glaucoma

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8148330B2 (en) * 2005-12-09 2012-04-03 The Board Of Trustees Of The Leland Stanford Junior University Modulation of synaptic maintenance
DK1991275T3 (en) * 2006-03-08 2014-12-08 Archemix Llc Complement aptamers AND ANTI-C5 AGENTS FOR USE IN THE TREATMENT OF EYE DISEASES
FI3380518T3 (fi) * 2015-11-24 2026-05-29 Annexon Inc Antikomplementtitekijä-C1Q:n Fab-fragmentteja ja niiden käyttöjä
CN116782940A (zh) * 2020-12-04 2023-09-19 安尼艾克松股份有限公司 用于治疗眼部疾病的组合物和方法

Also Published As

Publication number Publication date
AU2023262202A1 (en) 2024-10-24
KR20250006238A (ko) 2025-01-10
US20250313614A1 (en) 2025-10-09
JP2025515485A (ja) 2025-05-15
IL316218A (en) 2024-12-01
WO2023212719A1 (en) 2023-11-02
CN119136830A (zh) 2024-12-13
EP4518896A1 (en) 2025-03-12
EP4518896A4 (en) 2026-08-12
CA3250843A1 (en) 2023-11-02

Similar Documents

Publication Publication Date Title
JP6571252B2 (ja) 網膜疾患を処置するための組成物および方法
Kalloniatis et al. Retinitis pigmentosa: understanding the clinical presentation, mechanisms and treatment options
US5941250A (en) Retinal tissue implantation method
Park et al. Retroprosthetic membrane: a complication of keratoprosthesis with broad consequences
BR9611750A (pt) Uso de um produto protéico de fator neurotrófico derivado de linhagem de célula glial (gdnf) processo para prover células fotorreceptoras para implante e composição
Hammer et al. Viscous corneal protection by sodium hyaluronate, chondroitin sulfate, and methylcellulose.
Basu et al. Boston type 1 based keratoprosthesis (Auro Kpro) and its modification (LVP Kpro) in chronic Stevens Johnson syndrome
JP2022513073A (ja) 生分解性組織置換インプラントおよびその使用
CL2023001596A1 (es) Composiciones y métodos para el tratamiento de enfermedades oculares
JP2017523983A5 (enExample)
Akrami et al. Evaluation of RPE65, CRALBP, VEGF, CD68, and tyrosinase gene expression in human retinal pigment epithelial cells cultured on amniotic membrane
Kutluer et al. Targeting molecular pathways for the treatment of inherited retinal degeneration
Lorach et al. Transplantation of mature photoreceptors in rodents with retinal degeneration
WO2014192853A1 (ja) 環状デバイス
Elliot et al. Estrogen receptor β protects against in vivo injury in RPE cells
Palva et al. Eustachian—tube patency in chronic ears preoperative evaluation correlated to postoperative results
Jadidi et al. Complications of intrastromal corneal ring implantation (keraring 355) using a femtosecond laser for channel creation
ES2186340T3 (es) Utilizacion de polipeptidos fgf-5 para la prevencion de la muerte de neuronas retinales y para el tratamiento de enfermedades oculares.
Villegas et al. Herpetic keratitis in a patient who used two different prostaglandin analogue ophthalmic solutions: a case report.
Mohanty et al. Neurodegenerative eye disorders: role of mitochondrial dynamics and genomics
CN115006594A (zh) 机械增强型脱细胞猪角膜后板层载体支架制备方法及应用
Grewal et al. Dehydrated allogenic human amniotic membrane graft for conjunctival surface reconstruction following removal of exposed scleral buckle
RU2508134C1 (ru) Способ лечения меланомы хориоидеи размером более 6,5 мм
WO2000053760A3 (en) Method of preventing the death of retinal neurons and treating ocular diseases
Khaqan et al. Comparative Analysis of Visual and Anatomical Outcomes of Drainage Retinotomy: LASER Alone Versus LASER with Amniotic Membrane Graft